Based on the information provided, it is recommended to consult with a healthcare professional before receiving any live vaccines after stopping Cosentyx (secukinumab) treatment.

Cosentyx is a biologic medication used to treat various conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The drug works by targeting a specific protein in the immune system, which can affect the body's response to infections and vaccines [1][2].

A study found that patients treated with secukinumab (Cosentyx) had a reduced response to the live attenuated influenza vaccine (LAIV) [2]. However, the study did not investigate the impact of secukinumab on other live vaccines.

The Cosentyx official website states that patients should follow general vaccination guidelines, and live vaccines should be administered at least four weeks prior to initiating Cosentyx therapy [3]. Nonetheless, the website does not provide specific guidance on receiving live vaccines after stopping Cosentyx treatment.

In summary, the available information suggests that Cosentyx may affect the body's response to live vaccines. Patients should consult their healthcare provider before receiving any live vaccines after stopping Cosentyx treatment.

Sources:

[1] DrugPatentWatch. (n.d.). COSENTYX. Retrieved from <https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX>

[2] Zanoni, G., et al. (2022). Impact of Secukinumab on Influenza Vaccine Response in Patients with Psoriasis. Dermatology and Therapy, 12(2), 559–571. <https://doi.org/10.1007/s13555-022-00603-2>

[3] Cosentyx. (n.d.). COVID-19 Vaccination and Cosentyx. Retrieved from <https://www.cosentyx.com/all/covid19>